WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 2 fonti

Dr Reddy's extends slide as semaglutide setback threatens first-mover edge

Supply disruption has cast doubt on Dr Reddy's ability to capitalise on its early lead, with brokerages warning that prolonged delay could allow competitors to gain ground, weaken pricing power and slow earnings growth

Raccontata daeconomictimes.indiatimes.comthehindubusinessline.com

Confronto fonti

2 prospettive sulla stessa storia
AI · summaries
thehindubusinessline.comStai leggendo6 g fa

Dr Reddy's extends slide as semaglutide setback threatens first-mover edge

Supply disruption has cast doubt on Dr Reddy's ability to capitalise on its early lead, with brokerages warning that prolonged delay could allow competitors to gain ground, weaken pricing power and slow earnings growth

originale
economictimes.indiatimes.com6 g fa

Dr Reddy's shares crash 9% in 2 days; brokerages slash target prices after semaglutide supply disruption.…

Dr Reddy's Laboratories shares extended their decline after the company delayed commercial supplies of its semaglutide product due to a quality-related API issue. While brokerages remain broadly positive on the…

Leggi questa versione → originale

Timeline cronologica

  1. giovedì 9 luglio 2026·economictimes.indiatimes.com

    Dr Reddy's shares slide 7% after delay in semaglutide supplies over quality concerns

    Dr Reddy's shares fell sharply on Thursday after the company delayed commercial supplies of its semaglutide product due to a quality issue involving the active pharmaceutical…

  2. venerdì 10 luglio 2026·thehindubusinessline.com

    Dr Reddy's extends slide as semaglutide setback threatens first-mover edge

    Supply disruption has cast doubt on Dr Reddy's ability to capitalise on its early lead, with brokerages warning that prolonged delay could allow competitors to gain ground, weaken…

  3. venerdì 10 luglio 2026·economictimes.indiatimes.com

    Dr Reddy's shares crash 9% in 2 days; brokerages slash target prices after semaglutide supply disruption. What lies ahead?

    Dr Reddy's Laboratories shares extended their decline after the company delayed commercial supplies of its semaglutide product due to a quality-related API issue. While brokerages…